MLT抑制E2诱发的大鼠垂体PRL瘤的增生涉及雌激素受体的作用

目的：探讨褪黑素（melatonin,MLT）抑制17-β-雌二醇（17-β-estradiol,E2）诱发垂体催乳素（prolactin,PRL）瘤的增生及其机制的初始阶段,MLT对雌激素受体的作用。方法：在体实验采用每日定时给各组SD大鼠分别皮下注射不同浓度的MLT,建立MLT抑制E2诱发的垂体PRL瘤增生的动物模型。离体实验采用原代培养细胞原位杂交方法,探讨垂体PRL瘤细胞MLT受体的表达、MLT对雌激素受体（ER）表达的作用;应用电泳迁移率改变（EMSA）的方法,观察MLT对雌激素受体（ER）与雌激素反应元件（ERE）结合的效应。结果：每只大鼠每日定时皮下注射0．25或0．50mg MLT能显著抑制E2诱发的垂体PRL瘤的增生（分别P〈0．01、P〈0．05）;F4诱发的垂体PRL瘤细胞内有MLT受体MLT1a和MLT1b;给0．25mg／day／rat MLT组的大鼠垂体PRL瘤细胞内ER的表达显著减少（P〈0．01）、ER与ERE的结合量显著降低（P〈0．01）。结论：一定剂量的MLT能显著抑制E2诱发的SD大鼠垂体PRL瘤的增生,其作用机制之一可能与MLT抑制ER的表达、及其部分阻断ER与ERE的结合有关。     

雌激素诱发大鼠原位与移植垂体催乳素瘤中催乳素基因与TGFα和TGFβ1基因的表达

利用本实验室建立的17β雌二醇(17βestradiol,E2)诱致SpragueDawley(SD)大鼠原位垂体和异体移植于肾囊的垂体同时形成催乳素(prolactin,PRL)瘤的动物模型,采用Northern印迹杂交方法,我们观察了E2长期作用(120d)后诱发的原位与移植垂体PRL瘤中PRL基因和两种转化生长因子(transforminggrowthfactor,TGF)TGFα和TGFβ1基因表达水平的改变。结果表明:在E2长期作用后,原位垂体与异体移植于肾囊,从而远离下丘脑的垂体均可形成垂体PRL瘤;原位与移植垂体PRL瘤中均表现PRL基因的高表达,但移植瘤中的PRL基因表达水平低于原位垂体瘤;此外,仅在原位垂体PRL瘤中发现上述两种转化生长因子呈较高水平的表达,移植垂体PRL瘤与正常垂体中均检测不到这两种转化生长因子的表达。上述结果提示,TGFα和TGFβ1可能涉及E2诱发的原位垂体PRL瘤形成;E2诱发原位与移植垂体形成PRL瘤的机制可能不尽相同     

褪黑素抑制雌二醇诱致的垂体PRL瘤生长与血浆PRL和过氧化脂质含量的关系

雄性大鼠皮下埋置17-β雌二醇(17-β-estradiol,E2)药泵诱发垂体催乳素PRL)瘤,并每日皮下注射褪黑素(melatonin,MLT)观察MLT对E2诱发PRL瘤生长的影响.另外,采用放免法和紫外分光光度法测定大鼠血浆PRL和过氧化脂质(peroxidativelipid,PL)浓度,观察PRL瘤重量与大鼠血浆浓度间的相关关系.实验结果显示,在对照组、0.05、0.25、0.50、1.00和2.00mgMLT组,PRL瘤重量分别为115.0±71.0、85.2±41.0、58.9±24.1、72.7±23.6、79.3±56.1、74.5±46.8mg;血浆PRL浓度分别为493.46±33.3、373.78±26.5、125.13±13.3、201.79±11.2、418.88±41.3、281.94±36.4ng/ml;血浆PL水平分别为1.21±0.23、0.89±0.32、0.92±0.27、0.64±0.24、0.41±0.14、0.43±0.21△D233/ml.相关性分析表明,PRL瘤重量与血浆PRL浓度间的相关系数为0.8738(P＜0.05),与血浆PL水平间的相关系数为0.5550(P＞0.05),血浆PRL浓度与血浆PL水平间的相关系数为0.2141(P＞0.05).该结果提示,(1)0.25(P＜0.01)、0.50(P＜0.05)mgMLT能有效抑制E2诱致的PRL瘤生长和PRL分泌,所有剂量的MLT均能抑制血浆PL的形成;(2)PRL瘤重量与血浆PRL浓度间呈正相关关系,PRL瘤重量与血浆PL水平间、以及血浆PRL浓度与血浆PL水平间均无相关关系.因此,我们认为,MLT抑制E2诱致的PRL瘤生长可能与MLT抑制PRL表达性分泌有关,但与MLT抗氧化作用无关.     

中药降乳散对大鼠催乳素瘤表达Pit-1的作用

目的研究中药降乳散对大鼠催乳素（PRL）瘤组织表达Pit-1的作用。方法用皮下植入雌激素的方法制备大鼠PRL瘤模型,将成功诱发出PRL瘤的大鼠随机分2组,分别给予安慰剂和中药降乳散灌胃,用药4周后处死动物,垂体称重,用放免法测定血清PRL水平。用反转录-PCR方法分析Pit-1在大鼠PRL瘤组织中的表达量。结果降乳散组大鼠血清PRL水平和垂体重量均明显低于安慰剂组（P〈0.001）,Pit-1 mRNA水平在降乳散组较安慰剂组明显降低（P〈0.001）。结论降低Pit-1的表达水平可能是中药降乳散抗PRL瘤的重要机制之一。     

17—β—雌二醇诱发SD大鼠催乳素瘤形成过程中催乳素基因的表达

给SD大鼠皮下埋植内含17－β－雌二醇硅橡胶管30、60、120天后,发现大鼠垂体重量随给药时间延长呈持续性增加;用放射免疫法测定血浆催乳素（prolactin,PRL)含量,亦明显依次升高;用Northern印迹杂交方法检测垂体细胞中PRL基因,发现PRLmRNA含量也依次有显著增加,但其增加却远低于血浆PRL含量的增加,提示17－β－雌二醇除了促进PRL基因的转录外,还可能增加PRL mRNA的翻译效率。     

转录因子E2F-1与垂体肿瘤转化基因（PTTG）在大鼠PRL瘤中的表达

目的通过检测垂体肿瘤转化基因（PTTG）与腺病毒E2启动子结合因子1（E2F-1）在大鼠催乳素（PRL）瘤中的表达来探讨两者在PRL瘤发生发展过程中的作用。方法 40只大鼠随机分为两组：实验组（E组,n=20）：皮下植入17β-雌二醇的方法诱发大鼠PRL瘤;对照组（C组,n=20）：皮下植入空白硅胶管。雌激素诱导10周后处死大鼠,心脏穿刺取血,4%多聚甲醛体内灌流取出脑垂体,称重,ELISA方法检测两组大鼠血清PRL水平,垂体组织行病理组织学观察,免疫组化SP方法检测两组大鼠垂体组织中PTTG蛋白质、E2F-1蛋白质的表达。结果雌二醇作用10周后,据垂体重量、垂体组织学变化和血清PRL水平证实PRL瘤诱导成功。PRL瘤组中,PTTG蛋白质、E2F-1蛋白质均明显高于对照组,差异具有统计学意义（P〈0.01）;且PTTG蛋白质和E2F-1蛋白质的表达呈明显正相关（γ=0.764,P〈0.01）。结论 PTTG与E2F-1在大鼠PRL瘤中共同过度表达,参与了大鼠PRL瘤的发生发展。     

雷洛昔酚对大鼠垂体的作用

目的 观察雷洛昔酚是否能诱发出催乳素瘤的动物模型以及对PRL水平的影响,以研究雷洛昔酚对大鼠垂体的作用.方法 雌性Wistar大鼠切除卵巢后,分别在皮下埋植含有雷洛昔酚、雌激素和空白硅胶管,术后8周处死大鼠,检测大鼠体重变化、垂体重量变化、血清催乳素(PRL)水平和垂体组织学变化.结果 雷洛昔酚组与阴性对照组大鼠体重无明显统计学差异,与雌激素组大鼠体重具有统计学差异(P＜0.05);雷洛昔酚组与阴性对照组大鼠垂体重相比无明显差异,与雌激素组大鼠垂体重相比具有统计学差异(P＜0.05);雌激素组大鼠血清PRL水平最高,阴性对照组血清PRL水平最低,雷洛昔酚组介于两者之间,分别与雌激素组、对照组相比较差异均具有统计学意义(P＜0.05);雷洛昔酚组与对照组垂体病理为正常细胞形态,雌激素组垂体病理为PRL瘤表现.结论 雷洛昔酚对大鼠垂体有一定的影响,但不能诱发催乳素瘤.     

人参茎叶皂甙对实验性高催乳素血症大鼠催乳素和动情周期的影响

目的和方法:采用异体垂体前叶移植的方法制造大鼠慢性高催乳素血症模型,探讨人参茎叶皂甙对高催乳素血症大鼠催乳素和动情周期的作用.结果:①垂体前叶移植大鼠血清PRL水平升高而原位垂体PRL含量降低,GSLS则使高催乳素血症大鼠血清PRL水平降低,原位垂体PRL含量降低;②高催乳素血症大鼠动情周期显著受到抑制,而GSLS可拮抗高催乳素血症对大鼠动情周期的抑制作用.结论:GSLS有治疗高催乳素血症的应用前景.     

浙东白鹅催乳素基因表达特点

克隆了浙东白鹅催乳素基因(Prolactin, PRL)的全序列, 并应用荧光定量PCR技术研究了浙东白鹅在产蛋期、就巢期和恢复期时催乳素基因在下丘脑、垂体和卵巢中的表达特点。结果表明, 浙东白鹅催乳素基因在就巢期、产蛋期和恢复期的表达量差异显著(P < 0.05), 在就巢期表达量最高, 产蛋期次之, 恢复期表达量最低。对不同组织PRL的表达量分析, 发现在垂体与卵巢中的表达量、卵巢与下丘脑的表达量均有极显著的差异(P < 0.01), 但在垂体与下丘脑中的表达量差异不显著(P > 0.05), 在垂体表达量最多, 其次是下丘脑, 卵巢中的表达量最低。因此, 浙东白鹅PRL基因在不同繁殖时期体内表达差异较大。     

乳腺特异性表达催乳素基因载体的构建与检测

催乳素(prolactin,PRL)可通过PRL-PRLR-JAK/STAT信号通路促进乳腺发育,启动并维持泌乳。为了探讨调控PRL基因表达对奶水牛产奶量的影响,该研究构建了乳腺特异性表达PRL基因的核移植载体并检测了其有效性。首先,利用RT-PCR方法克隆得到804 bp的水牛PRL基因编码区;而后逐步采用酶切加连接方法,依次将PRL基因、β-酪蛋白(β-casein,BCN)启动子和标记基因插入p IFN-BCNpoly A质粒中,构建得到14.2 Kb的转PRL基因载体。将表达载体瞬时转染人Bcap-37细胞系,经RT-PCR检测发现,目的基因PRL可在该细胞系中表达。将该载体转入水牛胎儿成纤维细胞中,通过核移植法获得了转PRL基因水牛克隆胚胎。该文结果表明,所构建的PRL核移植载体可表达PRL基因,并可用于生产转PRL基因克隆水牛胚胎。     

垂体催乳素瘤的病因及发病机制的实验研究

应用在同一只雄性ＳＤ大鼠中,保留原位垂体并在肾囊内植入一异体垂体,同时背部埋植装有１７－β－雌二醇（１７－β－ｅｓｔｒａｄｉｏｌ,Ｅ２）的药泵,经Ｅ２在体作用６０￣１２０天后,其原位垂体和异体移植入肾囊的垂体同时形成２垂体催乳素（ｐｒｏｌａｃｔｉｎ,ＰＲＬ）瘤的动物模型,研究ＰＲＬ瘤的发病机制。结果表明,Ｅ２长期作用可诱发原位垂体和远离下丘脑的移植垂体同时形成ＰＲＬ瘤,并伴高ＰＲＬ血症和ＰＲＬ基因     

雌激素诱发大鼠原位与移植垂体催乳素瘤中催乳素基因与TGFα和TGF …

利用本实验室建立的１７β－雌二醇诱致Ｓｐｒａｇｕｅ－Ｄａｗｌｅｙ（ＳＤ）大鼠原位垂体和异体移植于肾囊的垂体同时形成催乳素瘤的动物模型,采用Ｎｏｒｔｈｅｍ印迹杂交方法,我们观察了Ｅ２长期作用（１２０ｄ）后诱发的原位与移植垂体ＰＲＬ瘤中ＰＲＬ基因和两种转化生长因子ＴＧＦα和ＴＧＦβ１基因表达水平的改变。结果表明：在Ｅ２长期作用后,原位垂体与异体移植于肾囊,从而远离下丘脑的垂体均可形成垂体ＰＲＬ瘤;原位     

A role for A/T-rich sequences and Pit-1/GHF-1 in a distal enhancer located in the human growth hormone locus control region with preferential pituitary activity in culture and transgenic mice.

A region located remotely upstream of the human pituitary GH (GH-N) gene and required for efficient GH-N gene expression in the pituitary of transgenic mice was cloned as a 1.6-kb Bg/II (1.6G) fragment. The 1.6G fragment in the forward or reverse orientation increased -496GH-N promoter activity significantly in pituitary GC and GH3 cells after gene transfer. The 1.6G fragment was also able to stimulate activity from a minimal thymidine kinase (TK) promoter which, unlike -496GH-N, lacked any Pit-1/GHF-1 element. Enhancer activity was localized by deletion analysis to a 203-bp region in the 3'-end of the 1.6G fragment and was characterized by the presence of a diffuse 136-bp nuclease-protected site, observed with pituitary (GC) but not nonpituitary (HeLa) cell nuclear protein. A major low-mobility complex was observed by electrophoretic mobility shift assay (EMSA) with GC cell nuclear protein, and the pattern was distinct from that seen with a HeLa cell extract. The nuclease-protected region contains three A/T-rich Pit-1/ GHF-1-like elements, and their disruption, in the context of the 203-bp region fused to the TK promoter, reduced enhancer activity significantly in pituitary cells in culture. A mutation in this region was also shown to decrease enhancer activity in transgenic mice and correlated with a decrease in the 203-bp enhancer region complex observed by EMSA. The participation of Pit-1/GHF-1 in this complex is indicated by competition studies with Pit-1/GHF-1 elements and antibodies, and direct binding of Pit-1/GHF-1 to the A/T-rich sequences was shown by EMSA using recombinant protein. These studies link the A/T-rich sequences to the distal enhancer activity associated with the GH locus control region in vitro and in vivo.     

Both Pit-1 and the estrogen receptor are required for estrogen responsiveness of the rat prolactin gene

To examine the functional relationship between distinct cis-active elements within the distal enhancer region of the rat PRL gene, we have used deletional and mutational analysis of that region in transient transfection studies in GH3 pituitary tumor cells. Results from these studies demonstrate that the region of the PRL distal enhancer containing the Pit-1-binding sites is critical not only for enhancer activity and the response to cAMP, but also for the response to estradiol. An interaction of the estrogen receptor with factors conferring basal enhancer activity is suggested by studies with a mutant distal enhancer region in which the PRL estrogen response element was converted to a palindromic estrogen response element. To directly examine potential interactions, cotransfection studies using PRL distal enhancer reporter gene constructs and expression vectors for Pit-1 and rat estrogen receptor were performed in two heterologous cell lines. The activity of the reporter gene under the control of the PRL distal enhancer linked to either the thymidine kinase promoter or the PRL proximal promoter was not significantly altered by cotransfection with the Pit-1 expression vector in COS-1 or RAT-1 cells. Coexpression of these reporter constructs and an expression vector for estrogen receptor resulted in only a slight response to estradiol. However, when both Pit-1 and estrogen receptor were cotransfected with the distal enhancer reporter gene, a marked induction was observed in response to estradiol, and this activity was dependent upon the concentration of the Pit-1 expression vector.(ABSTRACT TRUNCATED AT 250 WORDS)     

Discrepancy between prolactin (PRL) messenger ribonucleic acid and PRL content in rat fetal pituitary cells: possible role of dopamine

Data are controversial concerning the time when PRL-synthesizing cells are detected for the first time in the rat pituitary. Using a very sensitive immunocytochemical technique, we could visualize only a few PRL cells before day 10 after birth. At that time, pituitary PRL was still 200 times less abundant than in the adult (on a tissue weight basis) whereas PRL mRNA per mg total RNA was only 80 times lower than in the adult. However, by in situ hybridization, we could demonstrate the presence of PRL mRNA in cells from fetal day 18 on. We have also followed the expression of GH gene in rat pituitary cells during development. In contrast to results obtained with PRL cells, quantitative analysis of cDNA probe hybridization to GH mRNA correlated well with measurements of immunostained cells. We found that PRL was released in the blood from fetal day 19 onwards. Thus, at that time PRL is synthesized and secreted but not stored. We therefore measured brain dopamine levels, and the data support the idea that the rise in dopamine levels after birth contributes to PRL storage. We confirmed in vitro that newborn pituitary cells can store PRL when cultured in the presence of dopamine.     

Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats

The process of angiogenesis has been found to be essential for the development of estrogen-induced pituitary prolactinoma in Fischer 344 rats. Thalidomide [(alpha-(N-phthalimido)-glutarimide] is known to be a potent immunomodulatory drug with antiangiogenic properties, but its effect on lactotroph cell secretory function and pituitary prolactinoma formation has not been described yet. The purpose of this study was to examine the effects of thalidomide on secretion of prolactin (PRL) and vascular endothelial growth factor (VEGF), cell proliferation, apoptosis and angiogenesis within the anterior pituitary gland in long-term diethylstilboestrol (DES)-treated male F344 rats in vivo and in vitro. It was found that DES sharply increased serum PRL and VEGF levels. On the other hand, simultaneous treatment of F344 rats with thalidomide for the last 15 days of the experiment attenuated the stimulatory effect of DES on PRL and VEGF secretion. It also diminished prolactin cell proliferation evaluated as the number of proliferating cell nuclear antigen (PCNA)-positive stained cell nuclei and increased the number of apoptotic bodies determined by the terminal deoxynucleotidyl-mediated dUTP nick-end labeling (TUNEL) method in sections of the DES-induced pituitary prolactinoma. The density of pituitary microvessels evaluated by microscopic counting of CD-31-positive blood vessels was also diminished by the tested drug. In addition, thalidomide (10(-4) to 10(-6) M) inhibited cell proliferation, prolactin and VEGF secretion from rat pituitary prolactinoma cells cultured in vitro. In conclusion, our results provide strong evidence for the antiprolactin and antitumor activity of thalidomide in experimentally DES-induced pituitary adenoma.